Deferiprone as Parkinson's disease modifier: quantification of 3-O-methyldopa/l-dopa plasmatic ratio in patients

被引：0
|
作者：
Charbonnier-Beaupel, F. [1 ]
Bihan, K. [1 ]
Zahr, N. [1 ]
Corvol, J. C. [1 ]
Devos, D. [2 ]
机构：
[1] Pitie Salpetriere, Paris, France
[2] CHU Lille, F-59037 Lille, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2013年 / 27卷
关键词：
Parkinson's disease; deferiprone; disease modifier; metabolic ratio;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：73 / 74
页数：2
相关论文
共 50 条
  • [31] L-Dopa Increases α-Synuclein DNA Methylation in Parkinson's Disease Patients In Vivo and In Vitro
    Schmitt, Ina
    Kaut, Oliver
    Khazneh, Hassan
    deBoni, Laura
    Ahmad, Ashar
    Berg, Daniela
    Klein, Christine
    Froehlich, Holger
    Wuelliner, UlIrich
    MOVEMENT DISORDERS, 2015, 30 (13) : 1794 - 1801
  • [32] The impact of L-DOPA and entacapon therapy on plasma level of homocysteine in Parkinson's disease patients
    Nevrly, M.
    Kanovsky, P.
    Vranova, H.
    Nestrasil, I.
    Langova, K.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2008, 71 (01) : 55 - 60
  • [33] L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma
    Dizdar, N
    Granérus, AK
    Hannestad, U
    Kullman, A
    Ljungdahl, Å
    Olsson, JE
    Kågedal, B
    ACTA NEUROLOGICA SCANDINAVICA, 1999, 100 (04): : 231 - 237
  • [34] L-Dopa Prodrugs: An Overview of Trends for Improving Parkinson's Disease Treatment
    Di Stefano, Antonio
    Sozio, Piera
    Cerasa, Laura Serafina
    Iannitelli, Antonio
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (32) : 3482 - 3493
  • [35] Acoustic analysis of prosody in females with Parkinson's disease: effect of L-Dopa
    Azevedo, LL
    Cardoso, F
    Reis, C
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (04) : 995 - 998
  • [36] Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease
    Del Bello, Fabio
    Giannella, Mario
    Giorgioni, Gianfabio
    Piergentili, Alessandro
    Quaglia, Wilma
    BIOMOLECULES, 2019, 9 (04):
  • [37] Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease
    DelDotto, P
    Colzi, A
    Musatti, E
    Benedetti, MS
    Persiani, S
    Fariello, R
    Bonuccelli, U
    CLINICAL NEUROPHARMACOLOGY, 1997, 20 (05) : 455 - 465
  • [38] Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease
    Marriott, J
    Bryant, B
    Kempster, P
    Shif, M
    Lewis, MM
    Horne, M
    JOURNAL OF CLINICAL NEUROSCIENCE, 1998, 5 (02) : 178 - 181
  • [39] Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease
    Nagashayana, N
    Sankarankutty, P
    Nampoothiri, MRV
    Mohan, PK
    Mohanakumar, KP
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 176 (02) : 124 - 127
  • [40] THE IMPACT OF L-DOPA ON ATTENTIONAL IMPAIRMENTS IN A RAT MODEL OF PARKINSON'S DISEASE
    Smith, Elizabeth S.
    Hardy, Gwendolyn A.
    Schallert, Timothy
    Lee, Hongjoo J.
    NEUROSCIENCE, 2016, 337 : 295 - 305
12345